Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | MBTPS1 | Q14703 | 2/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25243811 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25233602 | 1.00 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25225394 | 0.86 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25225150 | 0.86 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25204401 | 0.86 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25205174 | 0.84 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25236812 | 0.84 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25509190 | 0.84 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25215536 | 0.84 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 | |
| SCHEMBL25230282 | 0.84 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3KCNH2MBTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049776-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR A SYSTEMIC TREATMENT OF DISEASES AND CONDITIONS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2025-02-13 | — | — | US | disclosed |
| EP-4183449-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049776-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR A SYSTEMIC TREATMENT OF DISEASES AND CONDITIONS | BECN1, TFEB, SQSTM1 | SLC6A4 982/4885SLC6A2 884/4885SLC6A3 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.